06/08/23 4:30 PMNasdaq : TVTX Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an activeRHEA-AIneutral
06/01/23 4:30 PMNasdaq : TVTX conferencesTravere Therapeutics to Present at Upcoming Investor ConferencesTravere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: William Blair 43 rd Annual Growth Stock Conference Tuesday, June 6, 2023, at 12:40 p.m. CT Jefferies HealthcareRHEA-AIneutral
05/31/23 7:00 AMNasdaq : TVTX clinical trialTravere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical HomocystinuriaData from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has been generally well-tolerated to date The Company is engaging with regulators and expects to initiate aRHEA-AIneutral
05/11/23 5:00 PMNasdaq : TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs,RHEA-AIvery positive
05/04/23 4:01 PMNasdaq : TVTX earningsTravere Therapeutics Reports First Quarter 2023 Financial ResultsFILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17 th , 2023; commercial launch underway Total net product sales of $50.3 million for the first quarter of 2023, including $3.0 million for FILSPARI SAN DIEGO, May 04,RHEA-AIneutral
05/01/23 4:05 PMNasdaq : TVTX clinical trialTravere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisThe DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatmentRHEA-AIneutral
04/26/23 4:30 PMNasdaq : TVTX conferencesearningsTravere Therapeutics to Report First Quarter 2023 Financial ResultsTravere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss theRHEA-AIneutral
04/13/23 5:00 PMNasdaq : TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs,RHEA-AIvery positive
04/01/23 4:30 AMNasdaq : TVTX clinical trialTravere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy andRHEA-AIneutral
03/28/23 4:30 PMNasdaq : TVTX conferencesTravere Therapeutics to Present at Upcoming Investor ConferencesTravere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days Tuesday, April 4, 2023, at 3:55 p.m. ETRHEA-AIneutral